{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:19Z","timestamp":1790011579220,"version":"4.0.1"},"reference-count":120,"publisher":"Elsevier","isbn-type":[{"value":"9780444634801","type":"print"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/bs.pmch.2014.10.001","type":"book-chapter","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T22:23:45Z","timestamp":1417472625000},"page":"135-184","source":"Crossref","is-referenced-by-count":24,"title":["A Perspective on the Next Generation of Antibacterial Agents Derived by Manipulation of Natural Products"],"prefix":"10.1016","author":[{"given":"Pamela","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmch.2014.10.001_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/17460441.2013.743991","article-title":"Multitarget ligands in antibacterial research: progress and opportunities","volume":"8","author":"East","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/35101544","article-title":"Structural basis for the interaction of antibiotics with the peptidyltransferase centre in eubacteria","volume":"413","author":"Schlunzen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrmicro3155","article-title":"Ribosome targeting antibiotics and mechanisms of bacterial resistance","volume":"12","author":"Wilson","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1109755","article-title":"A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics","volume":"308","author":"Charest","year":"2005","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0025","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/nbt1265","article-title":"Molecular engineering approaches to peptide, polyketide and other antibiotics","volume":"24","author":"Baltz","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0030","series-title":"antibiotic discovery and development","first-page":"79","article-title":"Beta-lactam antibiotics","author":"Page","year":"2012"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0035","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1021\/ja00090a005","article-title":"Dissection of the contributions towards dimerization of glycopeptides antibiotics","volume":"116","author":"Mackay","year":"1994","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1074-5521(96)90079-4","article-title":"Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story","volume":"3","author":"Walsh","year":"1996","journal-title":"Chem Biol"},{"issue":"Suppl. 5","key":"10.1016\/bs.pmch.2014.10.001_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1120009X.2000.11782313","article-title":"Comparative pharmacokinetics of teicoplanin and vancomycin","volume":"12","author":"Harding","year":"2000","journal-title":"J Chemother"},{"issue":"Suppl. 5","key":"10.1016\/bs.pmch.2014.10.001_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1120009X.2000.11782312","article-title":"Teichoplanin chemistry and microbiology","volume":"12","author":"Parenti","year":"2000","journal-title":"J Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.7164\/antibiotics.41.1430","article-title":"Synthesis and antibacterial evaluation of N-alkyl vancomycins","volume":"41","author":"Nagaryan","year":"1988","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0060","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1021\/ja00090a006","article-title":"Glycopeptide antibiotic activity and the possible role of dimerization: a model for biological signalling","volume":"116","author":"Mackay","year":"1994","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1074-5521(00)80008-3","article-title":"Binding of glycopeptides antibiotics to a model of a vancomycin-resistant bacterium","volume":"6","author":"Williams","year":"1999","journal-title":"Chem Biol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7164\/antibiotics.51.945","article-title":"Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides","volume":"51","author":"Snyder","year":"1988","journal-title":"J Antibiot"},{"issue":"Suppl 3","key":"10.1016\/bs.pmch.2014.10.001_bb0075","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0080","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time\u2013kill kinetics of oritavancin and comparator agents against Staphylococcus aureus Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187152110790886745","article-title":"From vancomycin to oritavancin: the discovery and development of a novellipoglycopeptide antibiotic","volume":"9","author":"Allen","year":"2010","journal-title":"Anti-infect Agents Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/13543784.16.5.717","article-title":"Review of dalbavancin, a novel semisynthetic lipoglycopeptide","volume":"16","author":"Kim","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0100","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptides","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: an investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides","volume":"7","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0115","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1517\/14656566.9.12.2197","article-title":"A new lipoglycopeptide: telavancin","volume":"9","author":"Nannini","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","article-title":"The history of the tetracyclines","volume":"1241","author":"Nelson","year":"2011","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00018-009-0172-6","article-title":"The tetracycline resistome","volume":"67","author":"Thaker","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/bs.pmch.2014.10.001_bb0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Bio Rev"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/jm00027a023","article-title":"Glycylcyclines 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines","volume":"37","author":"Sum","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0140","series-title":"Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections; 2010","author":"Drug Safety Communication","year":"2010"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0145","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1021\/jo030047d","article-title":"Versatile and facile synthesis of Diverse semisynthetic tetracycline derivatives via Pd-catalysed reactions","volume":"68","author":"Nelson","year":"2003","journal-title":"J Org Chem"},{"issue":"1","key":"10.1016\/bs.pmch.2014.10.001_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1358\/dof.2009.034.01.1324393","article-title":"Amadacycline","volume":"34","author":"Wang","year":"2009","journal-title":"Drugs Future"},{"issue":"2","key":"10.1016\/bs.pmch.2014.10.001_bb0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/bs.pmch.2014.10.001_bb0160","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanisms of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0165","doi-asserted-by":"crossref","first-page":"17913","DOI":"10.1021\/ja806629e","article-title":"A robust platform for the synthesis of new tetracycline antibiotics","volume":"130","author":"Sun","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0170","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1021\/jm401211t","article-title":"Synthesis and Biological evaluation of 8-aminomethyl tetracycline derivatives as novel antibacterial agents","volume":"55","author":"Clark","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/jm1015389","article-title":"8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents","volume":"54","author":"Clark","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0180","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/jm1015395","article-title":"Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogues","volume":"54","author":"Sun","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0185","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broadspectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/jm201467r","article-title":"Fluorocyclines 2. Optimisation of the C-9 side chain for antibacterial activity and oral efficacy","volume":"55","author":"Clark","year":"2012","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0195","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434, a novel fluorocycline against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/bs.pmch.2014.10.001_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1358\/dof.2014.039.04.2135181","article-title":"Eravacycline","volume":"39","author":"Chopra","year":"2014","journal-title":"Drugs Future"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0205","unstructured":"Xiao X, Deng Y, Sun C, Hunt D, Clark R, Fyfe C, et al. Novel 7-CF3-8-heterocyclyl tetracyclines with promising antibacterial activity against Gram-positive and Gram-negative pathogens, including pseudomonas aeruginosa. Poster F-632 presented at ICAAC 2013; Denver, USA. Available from: http:\/\/tphase.com\/TPhase\/media\/TetraPhase\/PDF\/Posters [cited 30 August 2014]."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/cr0301088","article-title":"Molecular insights into aminoglycoside action and resistance","volume":"105","author":"Magnet","year":"2005","journal-title":"Chem Rev"},{"issue":"4","key":"10.1016\/bs.pmch.2014.10.001_bb0215","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","article-title":"Aminoglycosides: activity and resistance","volume":"43","author":"Mingeot-Leclerq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0220","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/13543776.2010.506189","article-title":"New aminoglycoside antibiotics","volume":"20","author":"Dozzo","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0225","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1016\/j.bmcl.2007.08.059","article-title":"Effect of varying the 4\u201d position of arbekacin derivatives on antibacterial activity against MRSA","volume":"17","author":"Haraiwa","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0230","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.bmcl.2007.04.065","article-title":"Synthesis and antibacterial activity of 5-deoxy-5-episubstituted arbekacin derivatives","volume":"17","author":"Haraiwa","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0235","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1021\/jm061200+","article-title":"Structure-based design, synthesis and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2\u2033 ether analogues of paromomycin","volume":"50","author":"Hanessian","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0240","unstructured":"Migawa MT, Wang X, Swayze E, Griffey RH. ISIS Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6\u2032,6\u2033 and 1 modified aminoglycoside antibiotics; 2010 PCT Int Appl. WO2010 030690."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0245","unstructured":"Aggen J, Goldblum AA, Linsell M, Dozzo P, Moser HE, Hildebrandt D, et al. Achaogen Inc. 2009 PCT Int Appl. WO2009 067692."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0250","unstructured":"Linsell M, Goldblum AA, Aggen J, Moser H, Hanessian S, Pachamuthu K, et al. Achaogen Inc. 2008 PCT Int Appl. WO2008124821."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","article-title":"Combating evolution with intelligent design: the neoglycoside ACHN-490","volume":"13","author":"Armstrong","year":"2010","journal-title":"Curr Opin Microbiol"},{"issue":"10","key":"10.1016\/bs.pmch.2014.10.001_bb0260","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent in vitro activity against Klebsiella Pneumoniae isolates","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0265","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0270","unstructured":"www.achaogen.com."},{"issue":"5","key":"10.1016\/bs.pmch.2014.10.001_bb0275","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclerq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0280","article-title":"Ototoxic potential of ACHN-490 compared to gentamicin and amikacin in the guinea pig","author":"Kostrub","year":"2010"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0285","unstructured":"Chaparian MG, Brady M, Moe S, Renikuntla BR, Gadthula S, Meneni S, et al. SelectX Pharmaceuticals, Inc. 4,6-Substituted 2,5-dideoxystrepamine aminoglycoside antibiotics; 2013 PCT Int Appl. WO2013 116480."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0290","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0295","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLS(B) resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0300","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s101560050011","article-title":"Mechanisms of bacterial resistance to macrolide antibiotics","volume":"5","author":"Nakajima","year":"1999","journal-title":"J Infect Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","article-title":"Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA","volume":"36","author":"Douthwaite","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0310","unstructured":"Lociuro S, Ege T, Andreotti D, Arena A, Gagliardi S, Palombi G, et al. 2014 PCT Int Appl. WO2014049356."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0315","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2011.06300.x","article-title":"Understanding the regulatory hurdles for antibacterial drug development in the post-Ketec world","volume":"1241","author":"Echols","year":"2011","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0320","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00044011-200121080-00001","article-title":"Comparative tolerability of intravenous azithromycin, clarithromycin and erythromycin in healthy volunteers","volume":"21","author":"Zimmermann","year":"2001","journal-title":"Clin Drug Invest"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0325","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.22620","article-title":"Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases","volume":"49","author":"Brinker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0330","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1128\/AAC.00840-10","article-title":"Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors","volume":"54","author":"Bertrand","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0335","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00860-10","article-title":"Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis","volume":"54","author":"Llano-Sotelo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0340","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/AAC.01123-09","article-title":"In vitro activity of solithromycin against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms","volume":"54","author":"McGhee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0345","unstructured":"Undheim K, Gunnes S. 2004 PCT Int Appl WO2004056843."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0350","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/md12010317","article-title":"Thiopeptide antibiotics: retrospective and recent advances","volume":"12","author":"Just-Baringo","year":"2014","journal-title":"Marine Drugs"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0355","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3382\/ps.2007-00249","article-title":"History of the use of antibiotic as growth promoters in European poultry feeds","volume":"86","author":"Castanon","year":"2007","journal-title":"Poult Sci"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0360","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1021\/ja026249t","article-title":"Conformation and absolute configuration of nocathiacin I determined by NMR spectroscopy and chiral capillary electrophoresis","volume":"124","author":"Constantine","year":"2002","journal-title":"J Am Chem Soc"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0365","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7164\/antibiotics.51.715","article-title":"MJ347-81F4 A and B, novel antibiotics from Amycolatopsis sp.: taxonomic characteristics, fermentation, and antimicrobial activity","volume":"51","author":"Sasaki","year":"1998","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bmcl.2003.09.061","article-title":"Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives","volume":"14","author":"Reguiero-Ren","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0375","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1021\/jo020385z","article-title":"Synthesis of novel nocathiacin-class antibiotics. Condensation of glycolaldehyde with primary amides and tandem reductive amination of amadori-rearranged 2-oxoethyl intermediates","volume":"67","author":"Hrnciar","year":"2002","journal-title":"J Org Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0380","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1021\/jo0261698","article-title":"Mild method for cleavage of dehydroalanine units: highly efficient conversion of nocathiacin I to nocathiacin IV","volume":"67","author":"Reguiero-Ren","year":"2002","journal-title":"J Org Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0385","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1016\/j.bmcl.2004.08.058","article-title":"Nocathiacin I analogues: synthesis, in vitro and in vivo biological activity of novel semi-synthetic thiazolyl peptide antibiotics","volume":"14","author":"Naidu","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0390","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.bmcl.2005.02.046","article-title":"Synthesis, in vitro and in vivo antibacterial activity of nocathiacin I thiol-Michael adducts","volume":"15","author":"Naidu","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0395","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.tetlet.2003.11.081","article-title":"Organic reactions in frozen water: michael addition of amines and thiols to the dehydroalanine side chain of nocathiacins","volume":"45","author":"Naidu","year":"2004","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0400","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1016\/j.bmcl.2006.03.079","article-title":"Synthesis and antibacterial activity of nocathiacin I analogues","volume":"16","author":"Naidu","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0405","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1021\/jo071115p","article-title":"Conversion of nocathiacin I to nocathiacin acid by a mild and selective cleavage of dehydroalanine","volume":"72","author":"Xu","year":"2007","journal-title":"J Org Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0410","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.biortech.2009.12.060","article-title":"Microbial generation of nocathiacin acid from nocathiacin I","volume":"101","author":"Wei","year":"2010","journal-title":"Bioresour Technol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0415","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.bmcl.2009.04.144","article-title":"Nocathiacin analogs: synthesis and antibacterial activity of novel water-soluble amides","volume":"19","author":"Xu","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0420","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bmcl.2012.10.065","article-title":"Synthesis and antibacterial activity of novel water-soluble nocathiacin I analogues","volume":"23","author":"Xu","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0425","unstructured":"Malabarba M, Cavaleri M, Mosconi G, Jabes D, Romano G. 2003 PCT Int Appl WO03105881."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0430","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/S0960-894X(03)00811-4","article-title":"Combinatorial modification of natural products: synthesis, and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: a-ring modifications","volume":"13","author":"Clough","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0435","first-page":"2517","article-title":"Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270A: identification of the cycloalkylcarboxylic acids","volume":"54","author":"La Marche","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0440","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/AAC.00582-11","article-title":"In vitro and in vivo activities of novel semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu","volume":"55","author":"Leeds","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0445","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1021\/jm201685h","article-title":"Discovery of LFF571: an investigational agent for Clostridium difficile infection","volume":"55","author":"La Marche","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0450","article-title":"Are pleuromutilin antibiotics finally fit for human use?","volume":"71\u201381","author":"Novak","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0455","doi-asserted-by":"crossref","first-page":"923","DOI":"10.7164\/antibiotics.29.923","article-title":"New pleuromutilin derivatives with enhanced antimicrobial activity:II structure:activity correlations","volume":"29","author":"Egger","year":"1976","journal-title":"J Antibiot"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0460","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1073\/pnas.0700041104","article-title":"Induced-fit tightens pleuromutilin binding to ribosomes and remote interactions enable their selectivity","volume":"104","author":"Davidovich","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0465","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1358\/dof.2000.025.11.858699","article-title":"Pleuromutilin antibiotics","volume":"25","author":"Hunt","year":"2000","journal-title":"Drugs Future"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0470","series-title":"Functional molecules from natural sources","first-page":"106","article-title":"Pleuromutilins: antibiotic optimisation for human therapy","author":"Jarvest","year":"2010"},{"issue":"2","key":"10.1016\/bs.pmch.2014.10.001_bb0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dof.2006.031.02.963570","article-title":"Retapamulin","volume":"31","author":"Boyd","year":"2006","journal-title":"Drugs Future"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0480","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.00178-06","article-title":"Selection of retapamulin, a novel pleuromutilin for topical use","volume":"50","author":"Rittenhouse","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0485","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0968-0896(00)00338-2","article-title":"Pleuromutilins. Part 1. The identification of novel mutilin-14 carbamates","volume":"9","author":"Brooks","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0490","unstructured":"Schmidt U, Wicha WW, Obermayr F, Novak R, Prince W. BC-3781: Evaluation of the CYP3A4 interaction potential. Poster 1524 presented at ECCMID; 2011, Milan."},{"issue":"5","key":"10.1016\/bs.pmch.2014.10.001_bb0495","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.02106-12","article-title":"Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections","volume":"57","author":"Prince","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0500","unstructured":"Wicha WW, Lell C, Strickmann DB, Heilmayer W, Ivezic-Schoenfeld Z, Prince WT. Safety, tolerability, and pharmacokinetics of orally administered BC-3781, a novel antimicrobial. Poster A-012 presented at ICAAC; 2013. Denver, USA. Available from: http:\/\/www.nabriva.com\/news-publications\/press-releases\/ [cited 16 June 2014]."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0505","unstructured":"Paukner S, Kollmann H, Thirring K, Heilmayer W, Ivezix-Schoenfeld Z. Antibacterial in vitro activity of novel extended spectrum pleuromutilins against Gram-positive and Gram-negative bacteria. Poster P-1678 presented at ECCMID; 2014, Barcelona."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0510","unstructured":"Wicha WW, Ivezix-Schoenfeld Z. In vivo activity of extended spectrum pleuromutilins in a murine sepsis model. Poster P-1680 presented at ECCMID; 2014, Barcelona."},{"issue":"6","key":"10.1016\/bs.pmch.2014.10.001_bb0515","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2217\/fmb.13.39","article-title":"Pharmacology of polymyxins: new insights into and \u201cold\u201d class of antibiotics","volume":"8","author":"Velkov","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0520","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1021\/bi000386q","article-title":"The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide","volume":"39","author":"Tsubery","year":"2000","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/bs.pmch.2014.10.001_bb0525","doi-asserted-by":"crossref","first-page":"11498","DOI":"10.1074\/jbc.M806587200","article-title":"Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy","volume":"284","author":"Mares","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/bs.pmch.2014.10.001_bb0530","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkt039","article-title":"Novel derivatives of polymyxins","volume":"68","author":"Vaara","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0535","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/jm900999h","article-title":"Structure-activity relationships of polymyxin antibiotics","volume":"53","author":"Velkov","year":"2010","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/bs.pmch.2014.10.001_bb0540","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/cpb.57.332","article-title":"Development of des-fatty-acyl polymyxin B derivatives with Pseudomonas-specific antimicrobial activity","volume":"57","author":"Katsuma","year":"2009","journal-title":"Chem Pharm Bull"},{"issue":"2","key":"10.1016\/bs.pmch.2014.10.001_bb0545","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/toxsci\/kft247","article-title":"Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers","volume":"137","author":"Keirstead","year":"2014","journal-title":"Tox Sci"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0550","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1128\/AAC.01333-12","article-title":"Pharmacokinetics and renal disposition of Polymyxin B in an animal model","volume":"56","author":"Abdelraouf","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/bs.pmch.2014.10.001_bb0555","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.tetlet.2007.01.071","article-title":"Preparation of tetra-Boc-protected polymyxin B nonapeptide","volume":"48","author":"O'Dowd","year":"2007","journal-title":"Tet Lett"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0560","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1248\/cpb.57.240","article-title":"Contribution of each amino acid residue in polymyxin B to antimicrobial and lipopolysaccharide binding activity","volume":"57","author":"Kanazawa","year":"2009","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0565","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1128\/AAC.00405-08","article-title":"Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents","volume":"52","author":"Vaara","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0570","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijantimicag.2012.10.005","article-title":"The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and Colistin to human kidney proximal tubular kidney cells","volume":"41","author":"Vaara","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0575","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkq072","article-title":"Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice","volume":"65","author":"Lundberg","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0580","unstructured":"Leese, RA. 2010 PCT Int Appl. WO2010 075416."},{"key":"10.1016\/bs.pmch.2014.10.001_bb0585","unstructured":"Coleman S, Deat T, Pawliuk R, Chavan, FB, Oleson JR. CB-182,804 is less nephrotoxic as compared to Polymyxin B in monkeys following seven days of repeated intravenous dosing. Poster F1-1630, ICAAC 2010, Boston, USA."},{"issue":"12","key":"10.1016\/bs.pmch.2014.10.001_bb0590","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1021\/jm400416u","article-title":"Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections","volume":"56","author":"Magee","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2014.10.001_bb0595","unstructured":"Saadi M, Duperchy E, Brown P, Dawson MJ, Wadman, SN. 2013 PCT Int. Appl. WO2013072695."},{"issue":"5","key":"10.1016\/bs.pmch.2014.10.001_bb0600","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/cb500080r","article-title":"Teaching \u2018old\u2019 polymyxins new tricks: new-generation lipopeptides targeting Gram negative \u2018superbugs\u2019","volume":"9","author":"Velkov","year":"2014","journal-title":"ACS Chem Biol"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646814000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646814000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T11:52:28Z","timestamp":1598529148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646814000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9780444634801"],"references-count":120,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2014.10.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}